Biosimilars or follow-on proteins are the terms given to biologicals that are similar to existing products presently in the market.

When patent on the original product has expired, it gives biotechnology companies the opportunity to market a similar product to that of the innovator, very much like the generic pharmaceutical companies.

The generic drug market is growing faster than the proprietary pharmaceutical market.  In 2006, the growth of patented pharmaceuticals slowed to below 10% while that of generic and or biosimilar products grew by 25% to reach US$55 billion worldwide.

The market for SciGen's portfolio of products is increasing as the global trend of governments and other healthcare organizations are looking to use lower-priced generic pharmaceuticals to provide high quality healthcare.